Company intelligence
Medicines for Europe
About Medicines for Europe
Medicines for Europe represents the generic, biosimilar and value-added medicines industries across Europe. Its vision is to provide sustainable access to high quality medicines, based on 5 important pillars: patients, quality, value, sustainability and partnership. Its members directly employ 190,000 people at over 400 manufacturing and 126 R&D sites in Europe and invest up to 17% of their turnover in R&D investment. Medicines for Europe member companies across Europe are both increasing access to medicines and driving improved health outcomes. They play a key role in creating sustainable European healthcare systems by continuing to provide high quality, effective generic medicines, whilst also innovating to create new biosimilar medicines and bringing to market value added medicines, which deliver better health outcomes, greater efficiency and/or improved safety in the hospital setting for patients.
Verified activity
Signals from Medicines for Europe
3 published signals
Presence & Recognition
Medicines for Europe attended the Annual Conference 2026 to discuss the strategic value of the off-patent medicines sector and public procurement frameworks.
Reported by Medicines for Europe
Partnerships
Medicines for Europe highlights that the off-patent medicines sector is a strategic partner in ensuring Europe has the capacity to manufacture medicines, adapt, and respond to health security needs.
Reported by Medicines for Europe
Legal & Regulatory
Medicines for Europe noted that Advocate General Juliane Kokott proposed annulling key provisions of the Extended Producer Responsibility (EPR) cost allocation under the EU Urban Wastewater Treatment Directive (UWWTD) that allocate at least 80% of quaternary treatment costs to the pharmaceutical and cosmetics industries.
Reported by Medicines for Europe